Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CAMP - US13463J1016 - Common Stock

5.92 USD
-0.02 (-0.34%)
Last: 12/24/2025, 8:16:57 PM
Fundamental Rating

3

Taking everything into account, CAMP scores 3 out of 10 in our fundamental rating. CAMP was compared to 530 industry peers in the Biotechnology industry. CAMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CAMP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAMP has reported negative net income.
In the past year CAMP has reported a negative cash flow from operations.
CAMP had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CAMP reported negative operating cash flow in multiple years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

CAMP's Return On Assets of -61.48% is in line compared to the rest of the industry. CAMP outperforms 41.89% of its industry peers.
With a Return On Equity value of -90.54%, CAMP perfoms like the industry average, outperforming 48.68% of the companies in the same industry.
Industry RankSector Rank
ROA -61.48%
ROE -90.54%
ROIC N/A
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

CAMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K 30K

More info and screens

5

2. Health

2.1 Basic Checks

CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
CAMP has about the same amout of shares outstanding than it did 1 year ago.
CAMP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CAMP has an improved debt to assets ratio.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 0.90, we must say that CAMP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CAMP (0.90) is better than 62.08% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CAMP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CAMP is in line with its industry, outperforming 50.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.9
ROIC/WACCN/A
WACC8.78%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CAMP has a Current Ratio of 9.83. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CAMP (9.83) is better than 80.19% of its industry peers.
CAMP has a Quick Ratio of 9.83. This indicates that CAMP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CAMP (9.83) is better than 80.75% of its industry peers.
Industry RankSector Rank
Current Ratio 9.83
Quick Ratio 9.83
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

CAMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.75%, which is quite impressive.
Looking at the last year, CAMP shows a very negative growth in Revenue. The Revenue has decreased by -94.64% in the last year.
CAMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -70.88% yearly.
EPS 1Y (TTM)79.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
Revenue 1Y (TTM)-94.64%
Revenue growth 3Y-87.17%
Revenue growth 5Y-70.88%
Sales Q2Q%N/A

3.2 Future

CAMP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
Based on estimates for the next years, CAMP will show a very strong growth in Revenue. The Revenue will grow by 211.05% on average per year.
EPS Next Y69.61%
EPS Next 2Y35.48%
EPS Next 3Y22.94%
EPS Next 5Y13.67%
Revenue Next Year2239.42%
Revenue Next 2Y106.23%
Revenue Next 3Y79.12%
Revenue Next 5Y211.05%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

CAMP's earnings are expected to grow with 22.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.48%
EPS Next 3Y22.94%

More info and screens

0

5. Dividend

5.1 Amount

CAMP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (12/24/2025, 8:16:57 PM)

5.92

-0.02 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)05-11 2026-05-11
Inst Owners54.67%
Inst Owner Change100.38%
Ins Owners1.46%
Ins Owner Change0.83%
Market Cap277.53M
Revenue(TTM)3.80M
Net Income(TTM)-53.12M
Analysts85
Price TargetN/A
Short Float %1.12%
Short Ratio3.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.59%
Min EPS beat(2)-12.73%
Max EPS beat(2)9.55%
EPS beat(4)2
Avg EPS beat(4)-56.84%
Min EPS beat(4)-237.33%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-285.46%
EPS beat(12)5
Avg EPS beat(12)-206.26%
EPS beat(16)8
Avg EPS beat(16)-154.85%
Revenue beat(2)2
Avg Revenue beat(2)97.25%
Min Revenue beat(2)49.89%
Max Revenue beat(2)144.61%
Revenue beat(4)4
Avg Revenue beat(4)950.01%
Min Revenue beat(4)49.89%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)459.47%
Revenue beat(12)6
Avg Revenue beat(12)305.91%
Revenue beat(16)6
Avg Revenue beat(16)226.06%
PT rev (1m)0%
PT rev (3m)-22.73%
EPS NQ rev (1m)1.03%
EPS NQ rev (3m)42.65%
EPS NY rev (1m)-7.47%
EPS NY rev (3m)24.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)24%
Revenue NY rev (1m)15.53%
Revenue NY rev (3m)-6.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 73.03
P/FCF N/A
P/OCF N/A
P/B 4.73
P/tB 4.73
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.08
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.48%
ROE -90.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.31%
ROA(5y)-45.58%
ROE(3y)-87.52%
ROE(5y)-75.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.95%
Cap/Sales 14.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.83
Quick Ratio 9.83
Altman-Z 0.9
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)174.95%
Cap/Depr(5y)129.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
EPS Next Y69.61%
EPS Next 2Y35.48%
EPS Next 3Y22.94%
EPS Next 5Y13.67%
Revenue 1Y (TTM)-94.64%
Revenue growth 3Y-87.17%
Revenue growth 5Y-70.88%
Sales Q2Q%N/A
Revenue Next Year2239.42%
Revenue Next 2Y106.23%
Revenue Next 3Y79.12%
Revenue Next 5Y211.05%
EBIT growth 1Y3.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.78%
EBIT Next 3Y-11.62%
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.9%
OCF growth 3YN/A
OCF growth 5YN/A

CAMP4 THERAPEUTICS CORP / CAMP FAQ

What is the fundamental rating for CAMP stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAMP.


What is the valuation status for CAMP stock?

ChartMill assigns a valuation rating of 1 / 10 to CAMP4 THERAPEUTICS CORP (CAMP). This can be considered as Overvalued.


Can you provide the profitability details for CAMP4 THERAPEUTICS CORP?

CAMP4 THERAPEUTICS CORP (CAMP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CAMP4 THERAPEUTICS CORP?

The Earnings per Share (EPS) of CAMP4 THERAPEUTICS CORP (CAMP) is expected to grow by 69.61% in the next year.